Dr Reddy's Laboratories EBITDA Margin 2010-2025 | RDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Dr Reddy's Laboratories average ebitda margin for 2024 was 28.32%, a 2.41% decline from 2023.
Dr Reddy's Laboratories average ebitda margin for 2023 was 29.02%, a 31.97% decline from 2022.
Dr Reddy's Laboratories average ebitda margin for 2022 was 21.99%, a 4.81% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Dr Reddy's Laboratories average ebitda margin for 2024 was 28.32%, a 2.41% decline from 2023.
Dr Reddy's Laboratories average ebitda margin for 2023 was 29.02%, a 31.97% decline from 2022.
Dr Reddy's Laboratories average ebitda margin for 2022 was 21.99%, a 4.81% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$18.4B
BridgeBio Pharma (BBIO)	$8.8B
Bausch Health Cos (BHC)	$2.3B
Supernus Pharmaceuticals (SUPN)	$1.8B
Amphastar Pharmaceuticals (AMPH)	$972M
Taysha Gene Therapies (TSHA)	$552M
Personalis (PSNL)	$547M
Assembly Biosciences (ASMB)	$143M
Sol-Gel Technologies (SLGL)	$23M
Evoke Pharma (EVOK)	$7M
Teligent (TLGT)	$0M